目的 探讨大株红景天胶囊联合苯磺酸氨氯地平胶囊治疗冠心病心绞痛的临床疗效。方法 选取2020年2月—2021年5月在天津市宁河区医院接受治疗的94例冠心病心绞痛患者，按照随机数字表法将94例患者分为对照组和治疗组，每组各包括47例患者。对照组患者口服苯磺酸氨氯地平胶囊，10 mg/次，1次/d。治疗组在对照组治疗的基础上口服大株红景天胶囊，4粒/次，3次/d。两组患者连续治疗2个月。观察两组的临床疗效，比较两组患者心绞痛症状、心功能指标和血管内皮功能指标水平。结果 治疗后，治疗组总有效率为95.74%，对照组总有效率为80.85%，组间有明显差异（P<0.05）。治疗后，两组心绞痛的发作频率、持续时间、视觉模拟评分法（VAS）均显著降低（P<0.05）；与对照组相比，治疗组心绞痛的发作频率、持续时间、VAS评分降低更明显（P<0.05）。治疗后，两组的左室射血分数（LVEF）明显升高，左心房内径（LAD）、舒张期室间隔厚度（IVST）明显降低（P<0.05）；治疗后，治疗组的LVEF高于对照组，LAD、IVST低于对照组，差异有统计学意义（P<0.05）。治疗后，两组的一氧化氮合成酶（eNOS）水平明显升高，内皮素-1（ET-1）、血栓素A2（TXA2）水平明显降低，差异有统计学意义（P<0.05）；治疗后，治疗组的eNOS水平比对照组高，ET-1、TXA2水平比对照组低，差异有统计学意义（P<0.05）。结论 大株红景天胶囊联合苯磺酸氨氯地平胶囊治疗冠心病心绞痛的疗效确切，能减轻心绞痛症状，改善心功能和血管内皮功能，安全性良好。

Objective To investigate the clinical efficacy of Dazhuhongjingtian Capsules combined with Amlodipine Besylate Capsules in treatment of angina pectoris of coronary heart disease. Methods Patients (94 cases) with angina pectoris of coronary heart disease in Tianjin Ninghe Hospital from February 2020 to May 2021 were divided into control and treatment groups according to the random number table method, and each group had 47 cases. Patients in the control group were po administered with Amlodipine Besylate Capsules, 10 mg/time, once daily. Patients in the treatment group were po administered with Dazhuhongjingtian Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and angina symptoms, cardiac function indexes and vascular endothelial indexes in two groups were compared. Results After treatment, the total effective rate was 95.74% in the treatment group and 80.85% in the control group, and there was a significant difference between two groups (P < 0.05). After treatment, the attack frequency and duration of angina pectoris and the VAS scores in two groups were significantly decreased (P < 0.05). Compared with the control group, the attack frequency and duration of angina pectoris and the VAS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the LVEF in two groups were significantly increased, but the LAD and IVST in two groups were significantly decreased (P < 0.05). After treatment, the LVEF in the treatment group was higher than that in the control group, but the LAD and IVST in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of eNOS in two groups were significantly increased, but the levels of ET-1 and TXA₂ in two groups were significantly decreased (P < 0.05). After treatment, the levels of eNOS in the treatment group were higher than those in the control group, but the levels of ET-1 and TXA₂ were lower than those in the control group (P < 0.05). Conclusion Dazhuhongjingtian Capsules combined with Amlodipine Besylate Capsules has clinical curative effect in treatment of angina pectoris of coronary heart disease, can reduce the symptoms of angina pectoris, improve cardiac function and vascular endothelial function, with good safety.

R972

河北省中医药管理局科研计划项目（2019311）